Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 5/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | HRH2 | P25021 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD1 | P21728 | 1/20 | 0.37 |
| ▸ | DRD5 | P21918 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5754019 | 0.99 | SLC2A1 (0.44) | SLC2A1LTA4HALDH1A1HPGDUSP2 | |
| SCHEMBL5751879 | 0.96 | SLC2A1 (0.47) | SLC2A1ALDH1A1HPGDUSP2HRH1 | |
| SCHEMBL5754108 | 0.93 | LTA4H (0.42) | LTA4HHRH1SLC6A4HRH3HRH2 | |
| SCHEMBL5749810 | 0.92 | LTA4H (0.42) | LTA4HALDH1A1HPGDHRH1SLC6A4 | |
| SCHEMBL5754721 | 0.91 | PLA2G7 (0.38) | SLC2A1LTA4HALDH1A1HPGDLMNA | |
| SCHEMBL5752522 | 0.91 | LTA4H (0.41) | SLC2A1LTA4HALDH1A1HPGDHRH1 | |
| SCHEMBL5753115 | 0.91 | LMNA (0.47) | LTA4HALDH1A1HPGDHRH1SLC6A4 | |
| SCHEMBL5751728 | 0.91 | LTA4H (0.41) | LTA4HALDH1A1HPGDHRH1SLC6A4 | |
| SCHEMBL5754338 | 0.91 | TDP1 (0.42) | SLC2A1LTA4HALDH1A1ALOX5HRH3 | |
| SCHEMBL5756296 | 0.91 | LTA4H (0.41) | LTA4HALDH1A1HPGDALOX5SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1099692-B1 | N,N-SUBSTITUTED CYCLIC AMINE DERIVATIVES | EISAI CO LTD (JP) | 2006-05-03 | — | — | EP | claimed |
| US-20050009814-A1 | Pharmaceutical composition containing gabapentin or pregabalin and N-type calcium channel antagonist | AJINOMOTO CO., INC. (JP) | 2005-01-13 | — | — | US | claimed |
| EP-1481673-A1 | MEDICINAL COMPOSITIONS CONTAINING GABAPENTIN OR PREGABALIN AND N-TYPE CALCIUM CHANNEL ANTAGONIST | Ajinomoto Co., Inc. (JP) | 2004-12-01 | — | — | EP | claimed |
| US-6737425-B1 | SUCH AS 1-((4-CYANO-5-METHYL-4-PHENYL)HEXYL)-4-(2-(4-FLUORO -PHENOXY)ETHYL)PIPERAZINE; NERVE SELECTIVE CALCIUM ANTAGONISTS | EISAI CO., LTD. (JP) | 2004-05-18 | — | — | US | claimed |
| US-6667412-B1 | Carboxylic acid, ester or alcohol derivatives; n,n-substi-tuted cyclic amine or phenylacetonitrile intermediates; low cost; stability, workability, final product purity | EISAI CO., LTD. (JP) | 2003-12-23 | — | — | US | claimed |
| EP-1099692-A1 | N,N-SUBSTITUTED CYCLIC AMINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2001-05-16 | — | — | EP | claimed |
| US-7713957-B2 | Pharmaceutical composition containing gabapentin or pregabalin and N-type calcium channel antagonist | AJINOMOTO CO., INC. (JP) | 2010-05-11 | — | — | US | disclosed |
| EP-1099692-B1 | N,N-SUBSTITUTED CYCLIC AMINE DERIVATIVES | EISAI CO LTD (JP) | 2006-05-03 | — | — | EP | disclosed |
| US-20050009814-A1 | Pharmaceutical composition containing gabapentin or pregabalin and N-type calcium channel antagonist | AJINOMOTO CO., INC. (JP) | 2005-01-13 | — | — | US | disclosed |
| EP-1481673-A1 | MEDICINAL COMPOSITIONS CONTAINING GABAPENTIN OR PREGABALIN AND N-TYPE CALCIUM CHANNEL ANTAGONIST | Ajinomoto Co., Inc. (JP) | 2004-12-01 | — | — | EP | disclosed |
| US-6737425-B1 | SUCH AS 1-((4-CYANO-5-METHYL-4-PHENYL)HEXYL)-4-(2-(4-FLUORO -PHENOXY)ETHYL)PIPERAZINE; NERVE SELECTIVE CALCIUM ANTAGONISTS | EISAI CO., LTD. (JP) | 2004-05-18 | — | — | US | disclosed |
| EP-1167348-A1 | NITRILE DERIVATIVES | Eisai Co., Ltd. (JP) | 2002-01-02 | — | — | EP | disclosed |
| EP-1099692-A1 | N,N-SUBSTITUTED CYCLIC AMINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2001-05-16 | — | — | EP | disclosed |
| JP-2000169462-A | N,N-SUBSTITUTED CYCLIC AMINE DERIVATIVE | EISAI CO LTD | 2000-06-20 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009814-A1 | Pharmaceutical composition containing gabapentin or pregabalin and N-type calcium channel antagonist | CACNA1B, CACNA1G, CACNA1C | SLC2A1 1226/4885LTA4H 1317/4885ALDH1A1 3427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.